TILRAY ($TLRY) posted quarterly earnings results on Tuesday, April 8th. The company reported earnings of -$0.10 per share, missing estimates of -$0.04 by $0.06. The ...

Tilray’s Q3 earnings show promising signs of improving fundamentals with expanding margins and effective cost management, combined with a clean balance sheet. Management’s strategy shift to ...

Tilray Brands, Inc. (NASDAQ:TLRY) Q3 2025 Earnings Call Transcript April 8, 2025 Tilray Brands, Inc. misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were $-0.04.

Tilray entered penny stock territory quite some time ago, but throughout April, it was literally worth pennies. It traded ...

Analysts expect Eton Pharmaceuticals to report an earnings per share (EPS) of $0.03. The announcement from Eton ...

Tilray Brands missed Q3 expectations but improved its balance sheet, with net debt at $14 million. Read why I maintain my strong buy rating on TLRY stock.

Despite short-term challenges, Tilray’s focus on margin improvement and strategic market expansion helped the company post earnings that beat expectations, despite missing revenue targets.

Tilray reported fiscal third-quarter 2025 earnings, with net revenue declining 1% year over year to $186 million. However, excluding the effect of currency, net revenue would have grown 2%.

Tilray Brands (NasdaqGS:TLRY) launched a new beverage line, "Cruisies," focusing on ready-to-drink cocktails. This product-related announcement coincided with a period when Tilray's shares rose 10%, ...

A total of 5 analyst ratings have been received for Zevra Therapeutics, with the consensus rating being Buy. The average one-year price target stands at $22.0, suggesting a potential 179.54% upside.